Practice Contact Information
Mass Eye and Ear, Mass General Hospital, Harvard Medical School
243 Charles St
Web Site: https://www.masseyeandear.org/find-a-physician/f/faden-daniel
Areas of surgical specialization in Head and Neck Surgery
Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon
Dr. Daniel Faden is a board-certified specialist in head and neck cancer surgery at Massachusetts Eye and Ear, Massachusetts General Hospital and Harvard Medical School. He earned his undergraduate degree from the University of Michigan, medical degree from Boston University School of Medicine, and completed residency training in otolaryngology–head and neck surgery at the University of California, San Francisco. He then pursued two clinical fellowships at the University of Pittsburgh Medical Center in advanced head and neck oncologic surgery and cranial base surgery.
Dr. Faden’s clinical practice focuses on providing comprehensive care for the entire spectrum of benign and malignant head and neck tumors, including oral cavity, oropharynx, larynx, endocrine (thyroid and parathyroid), cutaneous (skin), salivary, sinonasal, and cranial base neoplasms. He has a particular interest and expertise in minimally invasive head and neck cancer surgery (TORS, TOLS, endoscopic cranial base surgery), precision/personalized head and neck oncology, and the management of HPV-associated head and neck cancers. He emphasizes a multidisciplinary approach to patient care to optimize oncologic, functional, and cosmetic outcomes for complex patients.
Dr. Faden is an active head and neck cancer translational investigator. Prior to arriving at Massachusetts Eye and Ear, he was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health/National Human Genome Research Institute and completed a postdoctoral research fellowship at the University of Pittsburgh. His research focuses on how different cellular alterations, such as DNA mutations and infection by human papilloma virus, effect the behavior of head and neck cancers, with the goal of translating findings into advancements in precision head and neck oncology care.
His efforts are centered on two overlapping arenas:
Understanding mutation acquisition and host-viral interactions in human papilloma virus (HPV)-associated head and neck cancer
A subset of head and neck cancers are caused by viral infection, including HPV. HPV-associated cancers behave differently than non-virally-associated head and neck cancers and are increasing in prevalence, surpassing cervical cancer as the most common HPV-associated malignancy in the U.S. Despite this, little is known regarding how HPV-associated head and neck cancers go from a cell that has become infected with HPV to a full-fledged cancer. Dr. Faden’s research aims to elucidate this process, including how HPV leads to host mutations and how features specific to the virus dictate the behavior of the tumor. Understanding this process is vital for improved diagnostics and treatment decision-making.
Defining how the genomic and immunogenomic landscape of head and neck cancers affects tumor behavior and treatment response
In recent years there has been a rapid accumulation of information regarding the genomic landscape of head and neck cancer. We now know that head and neck cancers possess a complex array of genomic and transcriptomic alterations and largely lack recurrent targetable mutations. In part because of this diversity, we have not yet seen the marked increase in knowledge translate to measurable improvements in patient care. Dr. Faden’s research is focused on understanding how these various acquired alterations impact tumor behavior and treatment response. To do so, he is studying unique and tightly curated head and neck cancer cohorts to help distinguish meaningful signatures from noise.
Faden DL, Gomez R, Alvarado D, Duvvuri U. Genomic correlates of exceptional response to ErbB3 inhibition in head and neck squamous cell carcinoma. JCO Precision Oncology. 2019.
Faden DL, Concha-Benavente F, Bhaswanth Chakka A, McMichael EL, Chandran U, Ferris RL. Immunogenomic Correlates of Response to Cetuximab Monotherapy in Head and Neck Squamous Cell Carcinoma. Head Neck. 2019. DOI:10.1002/hed.25726
Faden DL, Hughes MA, Lavigne P, Jankowitz BT, Wang EW, Fernandez-Miranda JC, Gardner PA, Snyderman CH. Diagnosis and endoscopic endonasal management of nontraumatic pseudoaneurysms of the cranial base. International forum of allergy & rhinology. 2018;8(5):641-7. Epub 2018/02/28. doi: 10.1002/alr.22080. PubMed PMID: 29485762.
Faden DL, Algazi A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. Journal of the National Cancer Institute. 2017;109(1). Epub 2016/09/28. doi: 10.1093/jnci/djw PubMed PMID: 27671684
Faden DL, Thomas S, Cantalupo PG, Agrawal N, Myers J, DeRisi J. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. Oral oncology. 2017;74:8-14. Epub 2017/11/07. doi: 10.1016/j.oraloncology.2017.09.002. PubMed PMID: 29103756
Faden DL, Asthana S, Tihan T, DeRisi J, Kliot M. Whole Exome Sequencing of Growing and Non-Growing Cutaneous Neurofibromas from a Single Patient with Neurofibromatosis Type 1. PloS one. 2017;12(1):e0170348. Epub 2017/01/19. doi: 10.1371/journal.pone.0170348. PubMed PMID: 28099461